Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML-NK Cells Combined With Atezolizumab in Relapsed or Refractory AML
NCT07011004Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started May 2025; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07011004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011004.